Identifikation frei zirkulierender Tumor- DNA durch den Nachweis tumorspezifischer Mikrosatelliten-Alterationen im Serum

Für das Urothelkarzinom der Harnblase gibt es derzeit keine serologischen Marker und keine suffizienten nicht-invasiven Untersuchungsmethoden für eine Karzinomdiagnose anhand von Urinproben. In der vorliegenden Arbeit wurde mit der Methode der Mikrosatellitenanalyse (MSA) eine genetische Charakteris...

Full description

Saved in:
Bibliographic Details
Main Author: Götzky, Raphael
Contributors: Knobloch, R. von (Prof. Dr. med.) (Thesis advisor)
Format: Dissertation
Language:German
Published: Philipps-Universität Marburg 2014
Operative Medizin
Subjects:
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!

1. Tsai YC, Nichols PW, Hiti Al, Williams Z, Skinner DG und Jones PA. Allelic losses of chromosome 9, 11, and 17 in human bladder cancer. Cancer Res. (1990), 50: 44-47.


2. Spruck CH, III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. (1994), 54: 784-788.


3. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, Espana P et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. (1999), 59: 3251- 3256.


4. Sozzi G, Conte D, Mariani L, Lo VS, Roz L, Lombardo C, Pierotti MA und Tavecchino L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. (2001), 61: 4675-4678.


5. Sandberg AA & Berger CS. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J.Urol. (1994) 151: 545-560.


6. Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthoff EC et al. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2009), 18(6): 1798-1806.


7. von Knobloch R, Brandt H, Schrader AJ, Heidenreich A, Hofmann R. Molecular serological detection of DNA alterations in 82 transitional cell carcinoma is highly sensitive and stage independent. Clin Cancer Res (2004): 10(3):988-93.


8. Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA und Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin.Cancer Res. (1999), 5: 2689-2692.


9. Shaw JA, Smith BM, Walsh T, Johnson S, Primrose L, Slade MJ, Walker RA und Coombes RC. Microsatellite alterations plasma DNA of primary breast cancer patients. Clin.Cancer Res. (2000), 6: 1046- 1051.


10. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur.Urol. (2008), 53(5): 909-916.


11. Shariat SF, Ashfaq R, Karakiewicz PI et al. Survivin expression is associated with bladder cancer presence, stage, progression and mortality. Cancer (2007), 109(6): 1106-1113.


12. Shaw ME & Knowles MA. Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes.Cancer Clin.Cancer Res. (1995), 13: 1-8.


13. von Knobloch R, Hegele A, Brandt H, Varga Z, Wille S, Kälble T, Heidenreich A, Hofmann R. High frequency of Serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis. Int J Cancer (2002), 98(6):889-894.


14. von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A und Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by flourescent microsatellite analysis. Int.J.Cancer (2001), Oct 1; 94(1): 67-72.


15. Stadler WM & Olopade OI. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol.Res. (1996), 24: 239-244.


16. von Knobloch R, Konrad L, Barth PJ, Brandt H, Wille S, Heidenreich A, Moll R, Hofmann R. Genetic pathways and new progression markers for prostate cancer defined by microsatellite allelotyping. Clin.Cancer Res. (2004) Feb, 1; 10(3):1064-1073.


17. Slaton JW, Benedict WF, Dinney CP. p53 in bladder cancer: mechanism of action, prognostic value and target for therapy. Urology (2001) May; 575) 852-859.


18. Tzai TS, Chen SH, Ho CC, Tsai YS, Cheng HC, Dai YC, Lin JS, Yang WH, Chow NH. Clinical significance of allelotype profiling for urothelial carinoma. Urology (2003), 62(2):378-384.


19. Selmy MA, Ibrahim GH, El Serafi TI und Ghobeish AA. Evaluation of urinary proepithelin as a potential biomarker for bladder cancer detection and prognosis in Egytian patients. Cancer biomarkers (2010), 7(3): 163-170.


20. Scelo G, Brennan P. The epidemiology of bladder and kidney cancer. Nature Clin.Pract.Urol. (2007), 4: 205-217.


21. Yuasa T, Yoshiki T, Isono T et al. Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer : detection of circulating cancer cells in the peripheral blood of metastatic patients. Int.J.Urol. (1999), 6(6): 286-292.


22. Williamson MP, Elder PA, Shaw ME, Devlin J und Knowles MA. P16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum.Mol.Genet. (1995a), 4: 1569-1577.


23. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW und Reuter VE. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J.Natl.Cancer.Inst (1993), 85: 53-59.


24. Steiner G, Schoenberg MP, Linn JF, Mao L und Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat.Med. (1997), 3: 621-624.


25. Sakaki M, Oka N, Nakanishi R et al. Serum level of galectin-3 in human bladder cancer. J.Med.Invest. (2008), 55(1-2): 127-132.


26. Willman CL. Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification. Mod.Pathol. (1999), 12: 218-228.


27. Weinstein RS, Coon JS, Schwartz D, Miller AW, III und Pauli BU. Pathology of superficial bladder cancer with emphasis on carcinoma in situ. Urology (1985), 26: 2-10.


28. Wiener HG, Vooijs GP, Hof-Grootenboer BV. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol (1993) Mar-Apr;37(2): 163–169.


29. Stenzl A, Cowan NC, De Santis M et al. The updated eau guidelines on muscle-invasive and metastatic bladder cancer. Eur.Urol. (2009), 55: 815-825.


30. Smith SD, Wheeler MA, Plescia J et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA (2001), 285: 324-328.


31. Simon M, Park TW, Köster G, Mahlberg R, Hackenbroch M, Boström J, Löning T, Schramm J. Alterations of INK4a(p16- p14ARF)/INK4b(p15) expression and telomerase activation in menignioma progression. J Neurooncol. (2001) Dec;55(3): 149-58.


32. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition oc cyclin D/CDK4. Nature (1993) Dec 16;366(6456): 704-707.


33. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, Fair WR, Herr HW und Reuter VE. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J.Urol. (1994), 152: 388-392.


34. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G und Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J.Urol. (1998), 159: 1876-1880.


35. Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B und Iczkowski K. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997), 80: 987-989.


36. Sarosdy MF, Schellhammer P, Bokinsky G et al. (2002) Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168: 1950–1954.


37. Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC und Vogelstein B. Clonal origin bladder cancer. N.Engl.J.Med. (1992), 326: 737-740.


38. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P und Discafani CM. Combinatorial chemoprevention of intestinal neoplasiea. Nat.Med. (2000), 6: 1024-1028.


39. Thomas F, Noon AP, Rubin N, Goepel JR, Catto JW. Comparative outcomes of primary, reccurent and high-risk non-muscle-invasive bladder cancer. Eur. Urol. (2012) Sep. 5 pii: S0302- 2838(12)01017-2.


40. Simon R, Eltze E, Schafer KL, Burger H, Semjonow A, Hertle L, Dockhorn-Dworniczak B, Terpe HJ und Bocker W. Cytogenetic analysis of multifocal baldder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res. (2001), 61: 355-362.


41. Tyrkus M, Powell I, Fakr W. Cytogenetic studies of carcinoma in situ of the bladder: prognostic implications. J.Urol. (1992), 148(1): 44-46.


42. Wyld DK, Selby P, Perren TJ, Jonas SK, Allen-Mersh TG, Wheeldon J und Burchill SA. Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction fpr cytokeratin 20. Int.J.Cancer (1998), 79: 288-293.


43. vom Dorp F, Kausch I, Jocham D. Diagnosis and treatment of non invasive urothelial carcinomas. Dtsch Arztebl (2007), 104(12):797-802.


44. von Kleist SU. Diagnostic significance if tumor markers. Cancer Res. (1980), 40: 2977-2978.


45. Sarkar S, Julicher KP, Burger MS, Della V, V, Larsen CJ, Yeager TR, Grossman TB, Nickells RW, Protzel C et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and rRb pathways in invasive human bladder cancers. Cancer Res. (2000), 60: 3862-3871.


46. Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N und Utirangura A. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Cli.Cancer Res. (2000), 6: 1046-1051.


47. Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R und Cooke T. C.erbB- 2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res. (1995), 55: 2422-2430.


48. Schneider A, Borgnat S, Lang H, Regine O, Lindner V, Kassem M, Suassine C, Oudet P, Jacqmin D et al. Evaluation of microsatellite analysis in urine sedimant for diagnosis of bladder cancer. Cancer Res. (2000), 60: 4617-4622.


49. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM et al. Evaluation of two new urinary tumor markers : bladder tumors fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clin.Cancer Res. (2000), 6: 3585-3594.


50. Zaak D, Karl A, Stepp H, Tritschler S, Tilki D, Bugert M, Knuechel R, Stief C. [Fluorescence cystoscopy at bladder cancer: Present trials.] Urologe A (2007), 46(11):1519-527.


51. Simoneau M, Aboulkassim TO, LaRue H, Rousseau F und Fradet Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene (1999), 18: 157-163.


52. Rübben H, Bubenzer J, Bokenkamp K, Lutzeyer W, Rathert P. Grading of transitional cell tumors of the urinary tract by urine cytology Urol Res (1979), 7: 83–91


53. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F und Waldman F. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. (1993), 53: 2199- 2203.


54. Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, GreenP, Hamilton SR et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science (1991), 252: 706-709.


55. Stroun M, Anker P, Lyautey J, Lederrey C und Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients.


56. Schullerus D, Herbers J, Chudek J, Kanamura H und Kovacs G. Loss of heterozygosity at chromosome 8p, 9p and 14q is associated with stage and garde of non-papillary renal cell carcinomas. J.Pathol. (1997), 183: 151-155.


57. Ruvkun G. Molecular biology. Glimpes of a tiny RNA world. Science (2001), 294: 797-799.


58. Theodorescu D, Frierson HF, Jr. Und Sikes RA. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J.Urol. (1999), 161: 1442-1448.


59. Sidransky D. Nucleic acid-based mathods for the detection o cancer. Science (1997), 278: 1054-1059.


60. Spruck CH, III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC und Jones PA. P16 gene in uncultured tumours. Nature (1994), 370: 183-184.


61. MP, Cairns P, Epstein JI, Schoenberg BP und Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res. (1995), 55: 5213-5216.


62. Sorensen GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ und Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidermiol.Biomarkers Prev. (1994), 3: 67-71.


63. Shariat SF, Karakiewicz PI, Godoy G et al. Survivin as a prognostic marker for urothelialcarcinoma of the bladder: A multicenter external validation study. Clin.Cancer Res. (2009), 15: 7012-7019.


64. Wilhelm M, Burgert P, Kenck C, Staehler G und Kovacs G. Terminal deletion of chromosome 3p sequences in nonpapillary renal cell carcinomas: a breakpoint cluster between loci D3S1285 and D3S1603. Cancer Res. (1995), 55: 5383-5385.


65. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(AFR), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. (1998) Sep 1;17(17):5001-5014.


66. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Ledderrey C, Lefort F, Rossier A, Chen XQ und Anker P. The origin and mechanism of circulating DNA. Ann.N.Y.Acad.Sci. (2000), 906: 161-168.


67. Sobin LH & Wittekind C. TNM classification of malignant tumors, John Wiley & Sons, Inc., (1997).


68. Silva JM, Gonzalez R, Dominguez G, Garcia JM, Espana P und Bonilla F. TP53 gene mutations in plasma DNA of cancer patients. Genes Chromosomes. Cancer (1999), 24: 160-161.


69. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL.Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitionasl cell carcinoma of the urinary tract following surgical treatment. J Urol (1996), 156: 363–367


70. Yu SL, Chen HY, Chang GC et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008), 13: 48-57.


71. Sauter G & Mihatsch MJ. Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! J.Pathol. (1998), 185: 339-341.


72. von Knobloch R, Bugert P, Jauch A, Kälble T und Kovacs G. Allelic changes at multiple regions of chromosome 5 are associated with progression of urinary bladder cancer. J.Pathol. (2000), 190: 163-168.


73. Shapiro B, Chakrabaty M, Cohn EM und Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer (1983), 51: 2116-2120.


74. Xu HJ, Cairns P, Hu SX, Knowles MA und Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int.J.Cancer (1993), 53: 781-784.


75. Tritschler S, Zaak D, Knuechel R, Stief CG. Urinzytologie und Urinmarker – Bedeutung für die Praxis. Urologe (2006), 45: 1441-1448.


76. Wakabayashi T, Sawabu N, Watanabe H, Morimoto H, Sugioka G und Takita Y. Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Am.J.Gastroenterol. (1996), 91: 1848-1851.


77. Rotem D, Cassel A, Lindenfeld N, Mecz Y, Sova Y, Resnick M und Stein A. Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur.Urol. (2000), 37: 601-604.


78. Schäfer A, Stephan C, Busch J et al. Diagnostic, prognostic and therapeutic implications of minorRNAs in urologic tumors. Nat.Rev.Urol. (2010), 7:286-297.


79. Steiner G & Sidransky D. Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites. Am.J.Pathol. (1996), 149: 1791-1795.


80. Steinman CR. Free DNA in serum and plasma from normal adults. J.Clin.Invest (1975), 56: 512-515.


81. Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, Waldman FM. Patterns of p53, erbB-2, and EGF-r expression in premalgnant lesions of the urinary bladder. Hum Pathol. (1995) Sep;26(9): 970-978.


82. Smith B, Selby P, Southgate J, Pittman K, Bradley C und Blair GE. Detection of melanoma cels in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet (1991), 338: 1227-1229.


83. Straub B, Müller M, Krause H, Goessl C, Schrader M, Heicappell R und Miller K. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen in the molecular staging of pelvic surgical margins after radical prostatectomy. Urology (2001), 57: 1006- 1011.


84. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, Shariat SF und Zlotta AR. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur.Urol. (2011), 60(3): 484-492.